Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ganymed Pharmaceuticals Closes EUR 45 Million Financing Round

Published: Monday, November 18, 2013
Last Updated: Monday, November 18, 2013
Bookmark and Share
Company to accelerate clinical development of antibodies IMAB362 and IMAB027 for the treatment of cancer.

Ganymed Pharmaceuticals AG has announced the completion of a EUR 45 million Series E financing from existing investors ATS Beteiligungsverwaltung GmbH, MIG Fond, and FCPB Gany GmbH.

Ganymed will use the proceeds to accelerate the clinical development of its lead program IMAB362, including completion of the ongoing Phase IIa and IIb clinical trials in gastroesophageal cancer, and to prepare this first-in-class antibody for a Phase III study.

Concomitantly, the Company will clinically validate its IVD test, CLAUDETECT™18.2, as a predictive companion diagnostic test to IMAB362.

The financing will also allow Ganymed to conduct a Phase I/II clinical study of IMAB027 in ovarian cancer and develop a companion diagnostic test for this antibody.

“We are very pleased that in the space of just three years, the Ganymed team has made immense progress in the clinical development of its lead program. In all clinical studies done so far, IMAB362 has shown exciting anticancer activity and safety data, suggesting that this antibody may well represent a breakthrough in the treatment of solid cancers,” said Thomas Strüngmann of ATS Beteiligungsverwaltung.

Prof. Rolf Krebs, Chairman of the Supervisory Board of Ganymed, commented: “The successful completion of this financing round is a strong testimony to the continuing solid commitment of Ganymed’s investors to the Company. We are truly excited that this financing allows us to accelerate the development of IMAB362, for which we have achieved promising preliminary results in the Phase IIa study earlier this year.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Ganymed’s IMAB027 Enters Phase I/II Clinical Trial for Ovarian Cancer
Second antibody from Ganymed’s ideal monoclonal antibody platform in the clinic.
Thursday, February 13, 2014
Ganymed Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
Conference will take place from January 13 to January 16, 2014 in San Francisco.
Thursday, December 26, 2013
Ganymed’s IMAB362 Receives Orphan Drug Designation from FDA and EMA
IMAB362 receives orphan drug designation for the treatment of pancreatic cancer.
Monday, October 21, 2013
Scientific News
Leukemia’s Surroundings Key to its Growth
Researchers at The University of Texas at Austin have discovered that a type of cancer found primarily in children can grow only when signaled to do so by other nearby cells that are noncancerous.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!